237 related articles for article (PubMed ID: 28181408)
21. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
[TBL] [Abstract][Full Text] [Related]
22. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
[TBL] [Abstract][Full Text] [Related]
23. Diallyl disulfide improves lipid metabolism by inhibiting PCSK9 expression and increasing LDL uptake via PI3K/Akt-SREBP2 pathway in HepG2 cells.
Wu YR; Li L; Sun XC; Wang J; Ma CY; Zhang Y; Qu HL; Xu RX; Li JJ
Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):322-332. PubMed ID: 33500108
[TBL] [Abstract][Full Text] [Related]
24. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels.
Mayer G; Poirier S; Seidah NG
J Biol Chem; 2008 Nov; 283(46):31791-801. PubMed ID: 18799458
[TBL] [Abstract][Full Text] [Related]
25. Cigarette smoke extract stimulates PCSK9 production in HepG2 cells via ROS/NF‑κB signaling.
Ma B; Wang X; Zhang R; Niu S; Rong Z; Ni L; Di X; Han Q; Liu C
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760160
[TBL] [Abstract][Full Text] [Related]
26. Pinostrobin Inhibits Proprotein Convertase Subtilisin/Kexin-type 9 (PCSK9) Gene Expression through the Modulation of FoxO3a Protein in HepG2 Cells.
Gao WY; Chen PY; Chen SF; Wu MJ; Chang HY; Yen JH
J Agric Food Chem; 2018 Jun; 66(24):6083-6093. PubMed ID: 29862818
[TBL] [Abstract][Full Text] [Related]
27. Hydrogen sulfide accumulates LDL receptor precursor via downregulating PCSK9 in HepG2 cells.
Huang Y; Ning K; Li WW; Lin G; Hou CL; Wang MJ; Zhu YC
Am J Physiol Cell Physiol; 2020 Dec; 319(6):C1082-C1096. PubMed ID: 32938225
[TBL] [Abstract][Full Text] [Related]
28. 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9.
Li HH; Li J; Zhang XJ; Li JM; Xi C; Wang WQ; Lu YL; Xuan LJ
Acta Pharmacol Sin; 2020 Mar; 41(3):327-335. PubMed ID: 31358898
[TBL] [Abstract][Full Text] [Related]
29. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
[TBL] [Abstract][Full Text] [Related]
30. Hydrogen sulfide inhibits PCSK9 expression through the PI3K/Akt‑SREBP‑2 signaling pathway to influence lipid metabolism in HepG2 cells.
Xiao J; Bai XQ; Liao L; Zhou M; Peng J; Xiang Q; Ren Z; Wen HY; Jiang ZS; Tang ZH; Wang MM; Liu LS
Int J Mol Med; 2019 May; 43(5):2055-2063. PubMed ID: 30864739
[TBL] [Abstract][Full Text] [Related]
31. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
[TBL] [Abstract][Full Text] [Related]
32. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
33. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
34. First Food-Derived Peptide Inhibitor of the Protein-Protein Interaction between Gain-of-Function PCSK9
Grazioso G; Bollati C; Sgrignani J; Arnoldi A; Lammi C
J Agric Food Chem; 2018 Oct; 66(40):10552-10557. PubMed ID: 30226051
[TBL] [Abstract][Full Text] [Related]
35. Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin.
Susan-Resiga D; Girard E; Essalmani R; Roubtsova A; Marcinkiewicz J; Derbali RM; Evagelidis A; Byun JH; Lebeau PF; Austin RC; Seidah NG
J Biol Chem; 2021 Oct; 297(4):101177. PubMed ID: 34508778
[TBL] [Abstract][Full Text] [Related]
36. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.
Seidah NG; Poirier S; Denis M; Parker R; Miao B; Mapelli C; Prat A; Wassef H; Davignon J; Hajjar KA; Mayer G
PLoS One; 2012; 7(7):e41865. PubMed ID: 22848640
[TBL] [Abstract][Full Text] [Related]
37. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
Yang SH; Xu RX; Cui CJ; Wang Y; Du Y; Chen ZG; Yao YH; Ma CY; Zhu CG; Guo YL; Wu NQ; Sun J; Chen BX; Li JJ
Cardiovasc Diabetol; 2018 Apr; 17(1):48. PubMed ID: 29618348
[TBL] [Abstract][Full Text] [Related]
38. Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression.
Wang J; Wang YS; Huang YP; Jiang CH; Gao M; Zheng X; Yin ZQ; Zhang J
Phytomedicine; 2021 Oct; 91():153688. PubMed ID: 34380071
[TBL] [Abstract][Full Text] [Related]
39. In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
Ando T; Yamamoto M; Yokoyama T; Horiuchi D; Kawakami T
J Biosci Bioeng; 2021 Mar; 131(3):326-332. PubMed ID: 33177004
[TBL] [Abstract][Full Text] [Related]
40. PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
Huang M; Zhao Z; Cao Q; You X; Wei S; Zhao J; Bai M; Chen Y
Metabolism; 2019 May; 94():88-95. PubMed ID: 30831144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
